Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China
Authors
Keywords
-
Journal
DISEASES OF THE ESOPHAGUS
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2022-06-02
DOI
10.1093/dote/doac031
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma ( NIC‐ESCC2019 ): a multicenter, phase 2 study
- (2022) Jun Liu et al. INTERNATIONAL JOURNAL OF CANCER
- Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
- (2022) Yuichiro Doki et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score
- (2022) A.G. Leone et al. ESMO Open
- Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
- (2022) Jun Liu et al. Journal for ImmunoTherapy of Cancer
- Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy
- (2021) E.C. Smyth et al. ANNALS OF ONCOLOGY
- Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single Arm Phase II Feasibility Trial (PERFECT)
- (2021) Tom van den Ende et al. CLINICAL CANCER RESEARCH
- Systematic profiling of ferroptosis gene signatures predicts prognostic factors in esophageal squamous cell carcinoma
- (2021) Tong Lu et al. Molecular Therapy-Oncolytics
- Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
- (2021) Ben M. Eyck et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
- (2021) Ronan J. Kelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- SHR‐1316 , an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study
- (2021) Lan Mu et al. Thoracic Cancer
- Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- (2021) Huiyan Luo et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
- (2021) Jong-Mu Sun et al. LANCET
- A multicenter single-arm trial of sintilimab in combination with chemotherapy for neoadjuvant treatment of resectable esophageal cancer (SIN-ICE study)
- (2021) Hongtao Duan et al. Annals of Translational Medicine
- Neoadjuvant checkpoint blockade for cancer immunotherapy
- (2020) Suzanne L. Topalian et al. SCIENCE
- Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
- (2020) Jing Huang et al. LANCET ONCOLOGY
- Learning from clinical trials of neoadjuvant checkpoint blockade
- (2020) Judith M. Versluis et al. NATURE MEDICINE
- Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
- (2020) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Investigative therapy for advanced esophageal cancer using the option for combined immunotherapy and chemotherapy
- (2020) Huan Wang et al. Immunotherapy
- Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010
- (2020) Shiliang Liu et al. EUROPEAN JOURNAL OF CANCER
- Strength of immune selection in tumors varies with sex and age
- (2020) Andrea Castro et al. Nature Communications
- Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy
- (2020) Yoshihiro Kakeji et al. Esophagus
- Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer
- (2020) Smita Sihag et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)
- (2020) Chengqiang Li et al. EUROPEAN JOURNAL OF CANCER
- The promise of neoadjuvant immunotherapy and surgery for cancer treatment
- (2019) Jake S O'Donnell et al. CLINICAL CANCER RESEARCH
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
- (2018) Gideon M. Blumenthal et al. Journal of Thoracic Oncology
- Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
- (2016) J. Liu et al. Cancer Discovery
- Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
- (2015) Joel Shapiro et al. LANCET ONCOLOGY
- Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
- (2015) Amylou C. Dueck et al. JAMA Oncology
- Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma
- (2013) R. L. G. M. Blom et al. DISEASES OF THE ESOPHAGUS
- Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
- (2012) P. van Hagen et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)
- (2011) Nobutoshi Ando et al. ANNALS OF SURGICAL ONCOLOGY
- The Clavien-Dindo Classification of Surgical Complications
- (2009) Pierre A. Clavien et al. ANNALS OF SURGERY
- Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction
- (2008) Jaffer A. Ajani CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More